K. Azuma

615 total citations
7 papers, 114 citations indexed

About

K. Azuma is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, K. Azuma has authored 7 papers receiving a total of 114 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 2 papers in Neurology. Recurrent topics in K. Azuma's work include Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). K. Azuma is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). K. Azuma collaborates with scholars based in Japan, United States and South Korea. K. Azuma's co-authors include C.-M. Tsai, Nobuyuki Katakami, Hiroshige Yoshioka, Tetsuya Mitsudomi, Toshiaki Takahashi, Nobuyuki Yamamoto, Mami Kurosaki, Myung‐Ju Ahn, Shiro Akinaga and T. Hirashima and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Cancers.

In The Last Decade

K. Azuma

7 papers receiving 111 citations

Peers

Countries citing papers authored by K. Azuma

Since Specialization

Citations

This map shows the geographic impact of K. Azuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Azuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Azuma more than expected).

Fields of papers citing papers by K. Azuma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Azuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Azuma. The network helps show where K. Azuma may publish in the future.

Co-authorship network of co-authors of K. Azuma

This figure shows the co-authorship network connecting the top 25 collaborators of K. Azuma. A scholar is included among the top collaborators of K. Azuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Azuma. K. Azuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study 2022 ·Cancers ·(unknown), Takehito Shukuya, Ryo Ko, Yusuke Okuma, Tomonobu Koizumi, Hisao Imai, Yuichi Takiguchi, Eisaku Miyauchi, Hiroshi Kagamu, Tomohide Sugiyama, K. Azuma, Yukiko Namba, Masahiro Yamasaki, Hisashi Tanaka, (unknown), (unknown), Osamu Ishimoto, Nobuyuki Koyama, Kunihiko Kobayashi, Kazuhisa Takahashi	2
2	Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026 2018 ·Annals of Oncology ·Yoshiyuki Kawashima, Tatsuro Fukuhara, Naoki Furuya, Hideyuki Saito, Katsuya Watanabe, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Akihiko Gemma, K. Azuma, Koichi Hagiwara, T. Nukiwa, Satoshi Morita, Kunihiko Kobayashi, Makoto Maemondo	1
3	Prognostic factors in patients with advanced thymic carcinoma treated with chemotherapy: A retrospective analysis of 289 patients from NEJ023 Study. 2016 ·Journal of Clinical Oncology ·Yusuke Okuma, Ryo Ko, Takehito Shukuya, Kazunari Tateishi, Hisao Imai, Eisaku Miyauchi, Akiko Fujiwara, Tomohide Sugiyama, K. Azuma, Keiko Muraki, Masahiro Yamasaki, Hisashi Tanaka, (unknown), (unknown), Osamu Ishimoto, Nobuyuki Koyama, Shoichi Kuyama, (unknown), Satoshi Morita, Kazuhisa Takahashi	1
4	A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study) 2015 ·Annals of Oncology ·Hiroshige Yoshioka, K. Azuma, Nobuyuki Yamamoto, Toshiaki Takahashi, Makoto Nishio, Nobuyuki Katakami, Myung‐Ju Ahn, T. Hirashima, Makoto Maemondo, (unknown), Mami Kurosaki, Shiro Akinaga, K. Park, C.-M. Tsai, Tomohide Tamura, Tetsuya Mitsudomi, Kazuhiko Nakagawa	89
5	A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer 2015 ·BMC Research Notes ·Hiroyuki Minemura, Hiroshi Yokouchi, K. Azuma, (unknown), (unknown), Kengo Oshima, Kenya Kanazawa, Yoshinori Tanino, Yayoi Inokoshi, Taeko Ishii, (unknown), Akio Oishi, Takashi Ishida, Mitsuru Munakata	6
6	Feasibility Re-evaluation of 75 mg/m2 Docetaxel in Japanese Patients with Previously Treated Non-small Cell Lung Cancer 2014 ·Japanese Journal of Clinical Oncology ·Kazuhiko Yamada, Hiroaki Takeoka, Yuji Mizoguchi, Fumiya Yamashita, Tsukasa Yoshida, Yoshio Zaizen, (unknown), Yoshiki Naito, K. Azuma, Tomoaki Hoshino	3
7	Clinical Practice in Management of Hydration for Lung Cancer Patients Receiving Cisplatin-based Chemotherapy in Japan: A Questionnaire Survey 2011 ·Japanese Journal of Clinical Oncology ·Kazuhiko Yamada, Tsukasa Yoshida, Yoshio Zaizen, (unknown), Yoshiko Naito, Fumiya Yamashita, Hiroaki Takeoka, Yuji Mizoguchi, K. Azuma	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact